Figure 3 Overall Survival: A. Patients Diagnosed with M0 Prostate Cancer; B. Patients Diagnosed with De Novo M1 Prostate Cancer

A. Patients diagnosed with M0 prostate cancer

**B. Patients diagnosed with de novo M1 prostate cancer**

**Figure 4. Metastasis-free Survival for Patients Diagnosed with M0 Prostate Cancer**

Table 3. Comparison of Presented Cohort with Prior Published Population Study by Castro, *et al.*[5]

Characteristics	Presented Study		Population Study	
	gATM	gBRCA2	gBRCA2	Non-carriers
Number of patients	45	45	61	1940
Age (range)	58 [44-81]	62 [40-75]	57.6 (41.7-88)	57.2 (32.3-88.9)
PSA (range)	23.7 [1.5-2555]	10.8 [1.31-750]	15.1 (0.5-761)	11.3 (0.3-7.800)
Gleason Grade 2 (%)	6 (13.3)	4 (8.9)	15 (24.6)	511 (26.3)
Gleason Grade > 3 (%)	29 (64.5%)	33 (73.3%)	23 (37.7)	299 (15.4)

Figure 5 Time on mCRPC Therapy with A. Abiraterone; B. Enzalutamide; C. Docetaxel; D. Platinum; E. PARPi

A) Abiraterone

B) Enzalutamide

Number at risk

—	16	16	13	11	7	6	5	5	4	4	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0
—	13	12	8	7	6	5	4	3	3	2	2	2	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

C) Docetaxel

Number at risk

—	18	17	14	6	2	1	0
—	21	20	12	5	0	0	0

D) Platinum

E) PARPi